ADAR Antikörper (AA 367-471)

Produktnummer ABIN7150633

Produktdetails anti-ADAR Antikörper

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Bindungsspezifität: AA 367-471

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser ADAR Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Double-stranded RNA-specific adenosine deaminase protein (367-471AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu ADAR

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Andere Bezeichnung: ADAR (ADAR Produkte)

Synonyme: red1 antikoerper, drada antikoerper, wu:fc22a02 antikoerper, adar1 antikoerper, dsRAD antikoerper, dsRAD-1 antikoerper, ADAR antikoerper, ADAR1 antikoerper, CG12598 antikoerper, Dmel\\CG12598 antikoerper, EG:BACN35H14.1 antikoerper, adar antikoerper, adr antikoerper, cg12598 antikoerper, dADAR antikoerper, dAdar antikoerper, hypnos-2 antikoerper, NV18763 antikoerper, AGS6 antikoerper, DRADA antikoerper, DSH antikoerper, DSRAD antikoerper, G1P1 antikoerper, IFI-4 antikoerper, IFI4 antikoerper, K88DSRBP antikoerper, P136 antikoerper, AV242451 antikoerper, Adar1 antikoerper, mZaADAR antikoerper, adenosine deaminase, RNA-specific antikoerper, adenosine deaminase, RNA-specific S homeolog antikoerper, adenosine deaminase, RNA specific antikoerper, Adenosine deaminase acting on RNA antikoerper, adenosine deaminase acting on RNA antikoerper, double-stranded RNA-specific editase 1 antikoerper, adar antikoerper, adar.S antikoerper, ADAR antikoerper, Adar antikoerper, CpipJ_CPIJ011849 antikoerper, LOC100114127 antikoerper

Hintergrund:

Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5\'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

Aliases: 136 kDa double-stranded RNA-binding protein antibody, 136 kDa double stranded RNA binding protein antibody, Adar 1 antibody, ADAR antibody, Adar1 antibody, Adenosine deaminase acting on RNA 1 A antibody, Adenosine deaminase RNA specific 1 antibody, Adenosine deaminase RNA specific antibody, Adenosine deaminase that act on RNA antibody, AGS6 antibody, AV242451 antibody, Double stranded RNA specific adenosine deaminase antibody, Double-stranded RNA-specific adenosine deaminase antibody, Double-stranded RNA-specific editase Adar antibody, DRADA antibody, Dsh antibody, Dsrad antibody, DSRAD_HUMAN antibody, dsRNA adenosine deaminase antibody, EC 3.5.4.- antibody, G1P1 antibody, IFI 4 antibody, IFI-4 antibody, IFI4 antibody, Ifi4 protein antibody, Interferon induced protein 4 antibody, Interferon inducible protein 4 antibody, Interferon-inducible protein 4 antibody, K88DSRBP antibody, mZaADAR antibody, P136 antibody, Pre-mRNA adenosine deaminase antibody, RNA adenosine deaminase 1 antibody, RNA-editing deaminase 1 antibody, RNA-editing enzyme 1 antibody

UniProt: P55265

Pathways: Protein targeting to Nucleus